Survodutide is a concrete bet on that principle, and the reason it is studied so intensively is that the bet is testable: if the glucagon axis truly adds something, it should show up as extra weight loss, extra liver-fat reduction, and a distinct safety signature relative to GLP-1 alone
Lin RZ, Im GB, Luo AC, Zhu Y, Hong X, Neumeyer J, et al
NQO1 supports the antioxidant network by catalyzing the two-electron reduction of quinones to hydroquinone, thereby bypassing semiquinone intermediates that can undergo redox cycling
Brodalumab is a novel antibody directed against one of the IL-17 receptors
Cell Physiol Biochem (2011) 27(3-4):2016
Integrating Peptides, Repurposed Drugs, and Supplements for Metabolic Health Peptides: GLP-1 agonists, GHRH/GHRPs ,MOTS-c, SS-31 and their role in enhancing insulin sensitivity